Mylan (NASDAQ:MYL) Upgraded at TheStreet

TheStreet upgraded shares of Mylan (NASDAQ:MYL) from a c rating to a b- rating in a research note published on Wednesday, January 17th.

MYL has been the topic of several other reports. Cowen reissued a market perform rating and set a $36.00 target price (up from $30.00) on shares of Mylan in a research note on Thursday, October 5th. Mizuho reaffirmed a buy rating and issued a $37.00 price target on shares of Mylan in a research note on Tuesday, October 24th. Zacks Investment Research downgraded shares of Mylan from a buy rating to a hold rating in a research note on Wednesday, November 8th. Cantor Fitzgerald set a $41.00 price target on shares of Mylan and gave the stock a hold rating in a research note on Tuesday, December 26th. Finally, UBS Group set a $46.00 price target on shares of Mylan and gave the stock a buy rating in a research note on Monday, December 4th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $44.65.

Shares of Mylan (NASDAQ MYL) traded up $0.03 during trading hours on Wednesday, reaching $39.28. 6,785,732 shares of the company’s stock traded hands, compared to its average volume of 5,613,673. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46. Mylan has a 52 week low of $29.39 and a 52 week high of $47.82. The firm has a market cap of $21,071.21, a P/E ratio of 24.40, a P/E/G ratio of 1.06 and a beta of 1.35.

In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the company’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.69% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MYL. Vanguard Group Inc. raised its position in Mylan by 12.0% in the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock worth $1,276,432,000 after purchasing an additional 3,531,974 shares in the last quarter. Pzena Investment Management LLC raised its position in Mylan by 84.1% in the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after purchasing an additional 10,381,697 shares in the last quarter. State Street Corp increased its holdings in shares of Mylan by 1.6% during the second quarter. State Street Corp now owns 20,498,541 shares of the company’s stock worth $795,751,000 after buying an additional 321,977 shares in the last quarter. Greenlight Capital Inc. increased its holdings in shares of Mylan by 0.4% during the third quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock worth $337,048,000 after buying an additional 42,600 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Mylan by 7.5% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,922,373 shares of the company’s stock worth $268,726,000 after buying an additional 480,500 shares in the last quarter. Institutional investors and hedge funds own 75.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://ledgergazette.com/2018/02/11/mylan-myl-rating-increased-to-b-at-thestreet.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply